Repligen’s (RGEN) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Repligen (NASDAQ:RGEN) in a research report sent to investors on Friday morning,Benzinga reports. They currently have a $180.00 price objective on the biotechnology company’s stock.

Other equities research analysts also recently issued research reports about the stock. TD Cowen assumed coverage on shares of Repligen in a research note on Monday, February 10th. They set a “buy” rating and a $200.00 target price for the company. Canaccord Genuity Group started coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. Wolfe Research began coverage on Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating for the company. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Finally, Canaccord Genuity Group initiated coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $183.36.

Repligen Trading Down 2.3 %

RGEN opened at $158.99 on Friday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a 52 week low of $113.50 and a 52 week high of $203.13. The business’s 50 day moving average is $155.22 and its two-hundred day moving average is $148.79.

Repligen (NASDAQ:RGEN) last announced its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. Analysts predict that Repligen will post 1.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Repligen

Large investors have recently added to or reduced their stakes in the business. CWM LLC lifted its holdings in shares of Repligen by 36.3% in the third quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 114 shares in the last quarter. Creative Planning lifted its stake in Repligen by 32.6% in the 3rd quarter. Creative Planning now owns 5,123 shares of the biotechnology company’s stock valued at $762,000 after buying an additional 1,259 shares in the last quarter. Blue Trust Inc. grew its holdings in Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 127 shares during the last quarter. Raymond James & Associates increased its position in Repligen by 49.3% during the third quarter. Raymond James & Associates now owns 82,277 shares of the biotechnology company’s stock worth $12,244,000 after buying an additional 27,158 shares in the last quarter. Finally, Greenleaf Trust acquired a new position in shares of Repligen in the third quarter worth $226,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.